Platelet membrane-coated nanoparticle-mediated targeting delivery of Rapamycin blocks atherosclerotic plaque development and stabilizes plaque in apolipoprotein E-deficient (ApoE−/−) mice - Song, Yanan; Huang, Zheyong; Liu, Xin; Pang, Zhiqing; Chen, Jing; Yang, Hongbo; Zhang, Ning; Cao, Zhonglian; Liu, Ming; Cao, Jiatian; Li, Chenguang; Yang, Xiangdong; et al. (Nanomedicine, 2019)
Keywords: Animals; Apolipoproteins E - genetics; Apolipoproteins E - physiology; Atherosclerosis; Atherosclerosis - drug therapy; Atherosclerosis - genetics; Atherosclerosis - pathology; Autophagy; Blood Platelets - physiology; Cell Membrane - chemistry; Cell Membrane - metabolism; Cells, Cultured; Drug Delivery Systems; Immunosuppressive Agents - pharmacology; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Nanoparticles - administration & dosage; Nanoparticles - chemistry; Plaque, Atherosclerotic - drug therapy; Plaque, Atherosclerotic - genetics; Plaque, Atherosclerotic - pathology; Platelet Adhesiveness; Platelet membrane-coated nanoparticle; Rapamycin; Sirolimus - pharmacology; Targeting delivery; RAP; vWF; PT; ALT; DLS; Targeting delivery; SMCs; Autophagy; HDL; Platelet membrane-coated nanoparticle; PNP; LDL; CM-NP; Atherosclerosis; BUN; ApoE−/− mice; RAP-PNP; AST; RAP-NP; Rapamycin; TC; APTT; PLGA; TG; TEM; DiD; HUVECs